Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer
Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele
Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele
View: Text | PDF
Research Article Cell biology Oncology

RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer

  • Text
  • PDF
Abstract

Acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) limits their therapeutic benefits in patients with high-grade serous ovarian cancer (HGSC). Identifying therapeutic vulnerabilities that function across distinct forms of acquired PARPi resistance is an urgent need. In BRCA2-deficient PARPi-naive cells, targeting RAD52 can be synthetic lethal with a PARPi, making RAD52 an attractive therapeutic target. However, this approach has not been tested in HGSC models of acquired PARPi resistance. Here, we assessed the effects of RAD52 loss in 2 distinct Brca2-deficient mouse models of HGSC with acquired PARPi resistance. RAD52 loss suppressed homologous recombination and single-strand annealing DNA repair activity in both models. Genetic depletion and pharmacologic inhibition of RAD52 restored PARPi sensitivity both in vitro and in vivo. Furthermore, RAD52 expression was elevated in a newly derived human model of BRCA2-deficient HGSC with acquired PARPi resistance. In this cell line, RAD52 inhibition synergized with a PARPi. Finally, elevated RAD52 expression was associated with poor survival in patients with HGSC. Collectively, these findings establish RAD52 as a clinically relevant therapeutic vulnerability in multiple models of HGSC with acquired PARPi resistance.

Authors

Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele

×

Figure 2

Genetic depletion of Rad52 re-sensitizes BRCA2-deficient ovarian cancer cells to olaparib.

Options: View larger image (or click on image) Download as PowerPoint
Genetic depletion of Rad52 re-sensitizes BRCA2-deficient ovarian cancer ...
(A) Western blot validation of Rad52 knockdown in HGS2-OR and Rad52 knockout in ID8-OR cells. (B and C) qRT-PCR of Rad52 mRNA in HGS2-OR (B) and ID8-OR (C) cells. (D) Cell viability after 5 days of treatment with 0–20 μM olaparib. (E–G) Clonogenic assay and quantification. (E) Representative images after 8 days of 5 μM olaparib treatment. (J and G) Quantification of clonogenic survival in HGS2-OR (F) and ID8-OR (G) cells. (H and I) HR activity in HGS2-OR (H) and ID8-OR (I) cells. (J and K) SSA activity in HGS2-OR (J) and ID8-OR (K) cells. (L) Quantification of γH2AX foci after 72 hours of 5 μM olaparib. Data represent mean ± SD from ≥3 independent experiments, with individual data points shown. Two-sided Student’s t tests were used for 2-group comparisons (B, D, F, H, and J). One-way ANOVA with Šídák’s multiple-comparison test was used for 3-group comparisons (C, G, I, and K). Kruskal-Wallis followed by Dunn’s test was used for nonparametric data (L). Black and red numbers above graphs are non-significant and significant, respectively, P values. HR, homologous recombination; Ola, olaparib; SSA, single-strand annealing; Veh, vehicle.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts